Donato Bonifazi

Do you work with advanced therapy medicinal products? Register now to take part in the 3rd multi-stakeholder meeting of the EU-Innovation network! Hosted by AIFA Agenzia Italiana del farmaco, this event provides an open forum to exchange views on how #innovation in #ATMP development can be translated into accessible treatment options for patients across Europe. 💻 🏢 https://lnkd.in/dwEti4vG Key topics will include: 💡 main challenges and barriers encountered from early development to access 💡 collaboration among stakeholders 💡 scientific and regulatory advice tools available for developers at European and national level Want to share your feedback? 💬 A first look at the results of a survey conducted among ATMP developers on the challenges and opportunities associated with the development of ATMPs will be presented at the event on 15 November. You can still complete the survey until Sunday. (Link in comments)

362

14 commenti

IceCure Medical's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious IEO Istituto Europeo di Oncologia (European Institute of Oncology) with Sponsorship from the Italian Ministry of Health: ❄ #PRECICE study, financed by the Umberto Veronesi Foundation and the Italian Ministry of Health, is led by multidisciplinary collaborators including breast surgeons, interventional radiologists, and breast imaging and pathology specialists ❄ PRECICE is exclusively using #ProSense to treat all 233 Luminal A and B patients >50 years of age with early-stage breast cancer, a wider population of patients than #ICE3 ❄ Article published in European Journal of Cancer Prevention describes the PRECICE study and presents the role of #cryoablation in the move toward de-escalation of surgical treatment Read more in our press release: https://lnkd.in/dsKisGvA Eyal Shamir Shay Levav Merav Nir Dotan Tlalit Bussi Tel-Tzure Galit (Bar) Malik Naum Muchnik Shad Good Ronen Tsimerman Orsi Franco

93

7 commenti

#mdpimedicina Open for Submissions! 📢"Urologic Oncology: Current Issues and Future Directions" is now open for #submissions! 👨‍🔬Guest Editors: Riccardo Bertolo,  Alessandro Antonelli and Francesco Ditonno 📅Deadline: 30 June 2025 🔍 More details: https://lnkd.in/dKmmWeMS This special issue belongs to the section "Oncology", https://lnkd.in/dAufTkwn #urology #oncology

8

SPCC (Sharing Progress in Cancer Care) - Strategic Leading and Management in Cancer Care Continuum https://lnkd.in/dZVC8nR3 SDA Bocconi European Cancer Organisation European School of Oncology Organisation of European Cancer Institutes (OECI) #Cancer #CancerCare #Leadership #Health #HealthCare #Medicine #Oncology #OncoDaily

15

📣 𝗦𝗔𝗩𝗘 𝗧𝗛𝗘 𝗗𝗔𝗧𝗘!   𝗩𝗔𝗫 𝗢𝗡 | 𝗩𝗮𝗰𝗰𝗶𝗻𝗲𝘀: 𝗣𝗿𝗲𝘀𝗲𝗻𝘁 𝗮𝗻𝗱 𝗙𝘂𝘁𝘂𝗿𝗲 𝗶𝗻 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗪𝗛𝗘𝗥𝗘: Milan, Italy 𝗪𝗛𝗘𝗡: October 1st, 2024 After decades of research and clinical trials, vaccines are beginning to impact patient outcomes. While the future is bright, we still have a long way to go.   An international meeting to share and discuss the latest findings and future perspectives on cancer vaccines. The objectives of the conference are to: - Present up-to-date data - Interpret clinical and scientific findings and predict potential impact - Recognize and characterize the hurdles that remain - Provide a vision for the future if hurdles are addressed 🔎 Stay tuned for the Scientific Program! ⏱ Registrations will open soon! Presidency: Paolo A. Ascierto, Bernard A. Fox PhD 👉 Info: [email protected] #Vivenko #VAXON #oncology #vaccines #clinicaltrials #savethedate

11

Recap of Exclusive Avicenna Members' Only Webinar! 🌟 Yesterday, members of Avicenna Alliance were privileged to attend a groundbreaking webinar titled "Empowering Ethical and Efficient Drug Development through Advanced Computational." Hosted by Martina Di Salvatore from Mimesis SRL, the webinar showcased the transformative potential of the Universal Immune System Simulator (UISS) in pharmaceutical research. Attendees gained valuable insights into how UISS is revolutionizing drug development through sophisticated computational models. Martina highlighted UISS's multi-scale, multi-organ, and three-dimensional agent-based simulation of the immune system, along with its ethical dimensions, including a significant reduction in traditional animal testing. The webinar provided a glimpse into the future of drug development, where advanced computational tools like UISS pave the way for more efficient, ethical, and successful outcomes. For those who missed it, stay tuned for future events hosted by Avicenna Alliance! Interested in becoming a member and gaining access to exclusive webinars like this one? Reach out to Avicenna Alliance at [email protected]. #AvicennaAlliance #DrugDevelopment #ComputationalScience #WebinarRecap #PharmaceuticalResearch #EthicalResearch

10

OPEN ACCESS Article The Impact of Inflammatory Bowel Diseases on Patients' Quality of Life and Work Functionality An Observational Study Leso, Veruscka MD, PhD; Testa, Anna MD, PhD; Pacella, Daniela PhD; Macrini, Maria Carmela MD; Villani, Guido Daniele MD; Gervetti, Paola MD; Barbato, Giuseppe MD; Rispo, Antonio MD, PhD; Castiglione, Fabiana MD, PhD; Iavicoli, Ivo MD, PhD Journal of Occupational and Environmental Medicine 66(11):p e567-e575, November 2024. | DOI: 10.1097/JOM.0000000000003213 Inflammatory bowel diseases (IBD), Crohn's disease and Ulcerative colitis, can affect the quality of life and work functionality of patients. A multidisciplinary IBD management, based on clinical strategies and an adequate management of patients' occupational health, is necessary to improve disease outcomes, and support patients' personal, social and professional lives. LEARNING OUTCOMES The study results demonstrated that inflammatory bowel diseases can affect the quality of life and work functionality of patients. Extraintestinal manifestations, comorbidities, activity, and severity of the disease were shown to play an influencing role on the quality of life and occupational outcomes. Upon reading this article, health professionals should provide a multidisciplinary IBD management that can improve disease outcomes and support personal, social, and professional lives of patients. https://lnkd.in/dkMeXMzc #JOEM

3

How to Use and Interpret Diagnostic and Monitoring Tests for Canine Leishmaniasis? Learn comprehensive strategies in our latest article here https://bit.ly/3UgSnrq Leishmaniasis will be the theme of the first day of JamSession24 - our annual free convention for continuing education in veterinary medicine. Register now here https://bit.ly/4cwgZ6t #VeterinaryMedicine #CanineHealth #Leishmaniasis

15

#Cabozantinib use in advanced or metastatic renal cell carcinoma (#RCC) is relatively recent, with limited real-world data on treatment persistence, adherence, and sequencing. An analysis of an integrated administrative database of 6.9 million Italians (2017-2020) included 113 RCC patients treated with cabozantinib. About 53.1% were highly adherent to the therapy, with a median treatment duration of 8.7 months. This study highlights cabozantinib’s use and its impact on patient management in Italy. | https://ow.ly/g7zZ50Sumek

2

📢 Where shall we meet? We are in Perugia (Veterinary Medicine Department, 08, 09/May/2024) 📢 Silvia Quaglio and Tommaso Sbrana are in Perugia, exhibiting IVTech products at the #conference "#Organoids revolutioning biomedicine through miniature #organ #models", organized by Università degli Studi di Perugia. Join us and visit our stand: we have our commercial devices and the new prototypes: #MultiDyn 6 well version, developped in H2020 Project ALTERNATIVE and #TEER 4 #LBs version. #Biology #Biotechnology #IVTech #TEER #Organoids

24

Validation of the HRD RAD51 assay as a predictive biomarker for VUS pathogenicity in BRCA1- Benedetta Pellegrino University of Parma #BreastAndOvarianCancer #Cancer #OncoDaily #Oncology #CancerCare

22

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Fondazione IRCCS Istituto Nazionale dei Tumori (INT) is a comprehensive cancer center certified by the Organisation of European Cancer Institutes (OECI) and a lead member of the @European Reference Network for Rare Cancers (EURACAN-ERN). It aims to deliver the best evidence-based care for cancer patients as well as to foster clinical and translational research in the field of oncology. INT is involved in the STREXIT 2 Project through the Sarcoma Service, an internationally recognized structure for the care of patients suffering from retroperitoneal sarcoma. INT will coordinate the recruitment of eligible patients for the STREXIT 2 study by referencing the network of centres participating in the project. INT will also be involved in educational initiatives focused on improving the referral of retroperitoneal sarcoma in experienced centres and training international healthcare professionals in the treatment of this disease. Dr. Alessandro Gronchi from the Fondazione IRCCS Istituto Nazionale dei Tumori is the study’s Principal Investigator and Co-Leader. Dr. Marco Fiore MD, FACS, FEBSh from the Fondazione IRCCS Istituto Nazionale dei Tumori is the study’s Co-Investigator. Find out more about the partners in the STREXIT2 project: https://lnkd.in/eQuVVVyA #STREXIT2_Horizon #HorizonEurope #EUCancerMission #SARCOMA #CancerResearch #ClinicalTrials #Cancer #RetroperitonealSarcoma #SoftTissueSarcoma European Commission

22

🔬 ‼ #Brillouin #microscopy at the #7thInternationalBioBrillouinconference. Last week Dr. Claudia Testi (post doc at Istituto Italiano di Tecnologia and involved in the #ivBM4PAP project under the European Innovation Council and SMEs Executive Agency (EISMEA)) showed her results, obtained in collaboration with IRCCS Ospedale San Raffaele on the use of Brillouin Microscopy in the characterization of mechanical features of murine bladder in the pathological condition of actinic cystitis. This work represents an additional step towards the common objective of the ivBM-4PAP Consortium: 🎯 Brillouin microscope as the only diagnostic tool with a fast, non-contact, label-free method with micrometric resolution for earlier detection of #neurodegenerative and #neurodevelopmental #diseases. For more information on the study: https://lnkd.in/drt93UVs. NTNU Faculty of Medicine and Health Sciences International BioBrillouin Society CrestOptics Université d'Angers Universidad de Zaragoza Università di Trento

12

𝗧𝗵𝗿𝗲𝗲 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝘀𝘁𝘀 𝘄𝗲𝗿𝗲 𝗴𝗿𝗮𝗻𝘁𝗲𝗱 𝘄𝗶𝘁𝗵 𝗮 𝗽𝗼𝘀𝘁𝗲𝗿 𝗮𝘄𝗮𝗿𝗱 in Florence at our 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝟮𝟯𝟴: 𝗜𝗺𝗺𝘂𝗻𝗼-𝗠𝗲𝗱𝗶𝗮𝘁𝗲𝗱 𝗗𝗶𝘀𝗲𝗮𝘀𝗲𝘀 𝗼𝗳 𝘁𝗵𝗲 𝗚𝗜 𝗧𝗿𝗮𝗰𝘁: 𝗪𝗵𝗲𝗿𝗲 𝗗𝗼 𝗪𝗲 𝗦𝘁𝗮𝗻𝗱? in Florence, Italy 𝟭𝘀𝘁 𝗔𝘄𝗮𝗿𝗱 𝟯.𝟬𝟬𝟬 𝗘𝘂𝗿𝗼: Chiara Amoroso (IT) " DEVELOPMENT OF AN ALGORITHM TO IDENTIFY THE BEST DONOR-RECIPIENT MATCH FORFMT IN IBD PATIENTS BASED ON IMMUNE SYSTEM/MICROBIOTA INTERACTIONS " 𝟮𝗻𝗱 𝗔𝘄𝗮𝗿𝗱 𝟮.𝟬𝟬𝟬 𝗘𝘂𝗿𝗼: Luisa Bertin (IT) “Efficacy of Orodispersible Budesonide in Eosinophilic Esophagitis: A Comprehensive Analysis of Clinical, Endoscopic, and Histological Outcomes” 𝟯𝗿𝗱 𝗔𝘄𝗮𝗿𝗱 𝟭.𝟬𝟬𝟬 𝗘𝘂𝗿𝗼: Mariam Mohamed Abdou (DE) „Vascular Leakage as an Early Diagnostic Marker for Inflammation in IBD: Insights from a Multiphoton Endomicroscopy Study in Mice” 𝗖𝗼𝗻𝗴𝗿𝗮𝘁𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀 𝘁𝗼 𝗲𝘃𝗲𝗿𝘆𝗯𝗼𝗱𝘆! #falkfoundation #posteraward #gitract #gastroenterology #congratulation #symposium

97

2 commenti

What is the future for #immunotherapy in #CancerCare? Alessandra Curioni Fontecedro explains that immunomodulation is still leading the way, but alternative sophisticated therapeutic strategies are emerging as technological advances lead to a greater understanding of the biological processes of #cancer. Particularly impressive results were presented at #ESMO24 with a combinatorial therapy of #CART cells targeting CLDN6 and a CLDN6-encoding CAR T cell-amplifying RNA vaccine, which increases presentation of the target to T cells for continuous stimulation. 📌Read her full editorial on the #ESMODailyReporter https://ow.ly/UqOm50TnVK4

47

I discussed the results of our work with Video Journal of Oncology (VJOncology) at ESMOBreast24 - Elisa Agostinetto ESMO - European Society for Medical Oncology Matteo Lambertini Eva Blondeaux Evandro de Azambuja #ESMOBreast24 #BreastCancer #Cancer #OncoDaily #Oncology

18

New Lecture Release! 📢 We are excited to present the lecture “Pre-transplant Information and Communicating Diagnosis to Patients” by Alessandra Agnese Grossi, University of Insubria, Varese, Italy, now available on Transplant Live. In this comprehensive lecture, Alessandra A. Grossi addresses the crucial topic of pre-transplant information, focusing on the communication of CMV diagnosis to patients. Key highlights include: • The complexity of pre-transplant information and the communication of risks associated with CMV. • Consideration of donor-, recipient-, transplant-, and immunosuppressive treatment-related factors. • Informing patients about the risks of disease transmission and the reactivation of latent infections post-transplant. • Practical guidance on the timing, content, and modality for effective CMV diagnosis communication. This lecture aims to introduce the relevance of pre-transplant information and provide considerations for meaningful communication of CMV diagnosis to patients. Access to Transplant Live is a benefit of the ESOT membership. This platform has been developed by ESOT Education with Luciano Potena and Luca Toti. 𝘛𝘩𝘪𝘴 𝘢𝘤𝘵𝘪𝘷𝘪𝘵𝘺 𝘪𝘴 𝘱𝘰𝘴𝘴𝘪𝘣𝘭𝘦 𝘵𝘩𝘢𝘯𝘬𝘴 𝘵𝘰 𝘵𝘩𝘦 𝘬𝘪𝘯𝘥 𝘴𝘶𝘱𝘱𝘰𝘳𝘵 𝘰𝘧 𝘉𝘪𝘰𝘵𝘦𝘴𝘵. #CMV #PoweredByESOT

15

1 commento